Descriptive only

Discontinuation due to adverse events

Polycystic ovary syndrome

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)Separate part 2 of a disconnected network

Randomized trials

Treatments

102

Participants

Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 2 of 2	Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 0 of 2
NCT02909933 S000499	100	not reported
S003101 S003101	100	not reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Asian ancestry or region: not reported by 2 of 2 trials
FlagOutcome assessment, analysis set: confounded with design: completers 1, randomized 1
FlagRisk of bias, blinding: confounded with design: double_blind 1, open_label 1
FlagRisk of bias, funding: confounded with design: mixed 1, non_industry 1
NoteOutcome assessment, time point: selected time points span 12 to 26 weeks

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT02909933	12	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2015	women 18 to menopause, PCOS phenotype A by Rotterdam criteria, BMI 30 or higher
S003101	26	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2014	premenopausal women 18 or older; Rotterdam PCOS; BMI 25 or more and/or C-peptide above 0.6 nmol/L; no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Source
NCT02909933	A1	LIRA_SC	12	arm, events	0 / 15	R0022935:Results
NCT02909933	A2	LIRAMETF_SC	12	arm, events	0 / 15	R0022935:Results
S003101	A1	LIRA_SC	26	arm, events	2 / 48	R0025661:Figure 1
S003101	A2	PLACEBO	26	arm, events	1 / 24	R0025661:Figure 1

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab